✦ LIBER ✦

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

✍ Scribed by Russell J. Schilder; John A. Blessing; Michael L. Pearl; Peter G. Rose

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dactinomycin in the Treatment of Recurre

✍ David H. Moore; John A. Blessing; Charles Dunton; Richard E. Buller; Gary C. Rei 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 33 KB

A phase II evaluation of weekly docetaxe

✍ Agustin A. Garcia; John A. Blessing; Susan Nolte; Robert S. Mannel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 135 KB

A phase II evaluation of aflibercept in

✍ Robert L. Coleman; Michael W. Sill; Heather A. Lankes; Amanda Nickles Fader; Nei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 246 KB

A Phase II Trial of Anastrozole in Advan

✍ Peter G. Rose; Virginia L. Brunetto; Linda VanLe; Jeffrey Bell; Joan L. Walker; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A phase II study of gemcitabine (gemzar,

✍ David L. Tait; John A. Blessing; James S. Hoffman; Kathleen N. Moore; Nick M. Sp 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase II Trial of Pyrazoloacridine in Pa

✍ Steven C. Plaxe; John A. Blessing; Nader Husseinzadeh; Kenneth D. Webster; Janet 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 39 KB